原发性胆汁性胆管炎的研究进展

Research advances in primary biliary cholangitis

原发性胆汁性胆管炎是一种慢性肝内胆汁淤积性疾病,文献报道其发病率和患病率不断提高。通过检查血清抗线粒体抗体M2亚型等特异性抗体或肝组织病理学检查可确定诊断。熊去氧胆酸是治疗本病的主要药物,但对熊去氧胆酸生化学应答欠佳者疾病进展快,目前尚无统一有效的治疗手段。加用布地奈德、非诺贝特、苯扎贝特或奥贝胆酸可能对部分患者有效,但仍需进一步临床研究验证。

Primary biliary cholangitis is a chronic intrahepatic cholestatic liver disease and has increasing incidence and prevalence rates,as is reported in the literature. Examination of specific antibodies including serum anti- mitochondrial antibody subtype M2 and liver histopathological examination help to make a definite diagnosis of this disease. Ursodeoxycholic acid（ UDCA） is often used for the treatment of this disease,but patients with an unsatisfactory biochemical response to UDCA tend to have rapid disease progression. At present,there are no effective treatment methods for such patients. The addition of budesonide,fenofibrate,bezafibrate,or obeticholic acid may be effective in these patients,but this needs to be verified by further clinical studies.